The American Medical Association calls for action on eight strategies to increase access to evidence-based opioid use disorder care

Rapid induction to extended-release buprenorphine 300-mg injection feasible and well tolerated for those using fentanyl

Predictors include history of overdose, higher opioid dose, three or more prescribers, any mental health diagnosis

Higher 90-day treatment retention rates seen with no higher risk for overdose

Implementation of opioid use disorder screening does not increase percentage of patients with new diagnosis

Opioid crisis hitting those without college education the hardest

Extended-release buprenorphine not cost-effective when transmucosal buprenorphine is available for treatment of OUD

Receipt of physical therapy and chiropractic care was low overall and lower across racial, ethnic minorities

Regardless of prognosis, panel deemed it appropriate to continue opioids, increase monitoring, and avoid opioid tapering

Court is asking the parties to show whether bankruptcy law allows for a blanket shield from all litigation by opioid victims